Product Description
PDE4 inhibitor (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567892/)
Mechanisms of Action: PDE4 Inhibitor
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Inflazyme
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Asthma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IPL512,602-2002 | P2 |
Completed |
Asthma |
None |